Shares of United Therapeutics Corporation (NASDAQ:UTHR) have been given an average recommendation of “Hold” by the fifteen research firms that are presently covering the firm, Marketbeat.com reports. Six investment analysts have rated the stock with a sell recommendation, seven have issued a hold recommendation and two have given a buy recommendation to the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $127.80.

Several research firms have commented on UTHR. BidaskClub cut shares of United Therapeutics Corporation from a “buy” rating to a “hold” rating in a research note on Wednesday, July 19th. Oppenheimer Holdings, Inc. reissued a “buy” rating on shares of United Therapeutics Corporation in a research note on Friday, September 8th. ValuEngine cut shares of United Therapeutics Corporation from a “strong-buy” rating to a “buy” rating in a research note on Friday, July 28th. Zacks Investment Research cut shares of United Therapeutics Corporation from a “hold” rating to a “sell” rating in a research note on Thursday, July 13th. Finally, Jefferies Group LLC reissued a “sell” rating and set a $105.00 target price on shares of United Therapeutics Corporation in a research note on Friday, July 14th.

Shares of United Therapeutics Corporation (NASDAQ UTHR) traded down 0.18% on Friday, reaching $120.79. 843,120 shares of the company’s stock traded hands. The company has a 50 day moving average price of $128.92 and a 200 day moving average price of $129.77. The firm has a market capitalization of $5.25 billion, a price-to-earnings ratio of 14.01 and a beta of 1.52. United Therapeutics Corporation has a 52 week low of $110.90 and a 52 week high of $169.89.

United Therapeutics Corporation (NASDAQ:UTHR) last released its earnings results on Thursday, July 27th. The biotechnology company reported ($1.25) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $3.61 by ($4.86). The company had revenue of $444.60 million for the quarter, compared to analyst estimates of $391.53 million. United Therapeutics Corporation had a net margin of 24.18% and a return on equity of 20.96%. The firm’s quarterly revenue was up 7.8% on a year-over-year basis. During the same period in the previous year, the business posted $4.42 EPS. On average, equities research analysts predict that United Therapeutics Corporation will post $10.09 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This report was posted by American Banking News and is the sole property of of American Banking News. If you are accessing this report on another website, it was illegally stolen and republished in violation of international copyright laws. The correct version of this report can be read at https://www.americanbankingnews.com/2017/09/16/united-therapeutics-corporation-uthr-given-average-recommendation-of-hold-by-brokerages.html.

In other United Therapeutics Corporation news, Director Christopher Causey sold 590 shares of the firm’s stock in a transaction dated Thursday, July 6th. The shares were sold at an average price of $132.61, for a total value of $78,239.90. Following the completion of the transaction, the director now directly owns 3,875 shares in the company, valued at $513,863.75. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Martine A. Rothblatt sold 1,234 shares of the firm’s stock in a transaction dated Thursday, June 22nd. The stock was sold at an average price of $132.32, for a total transaction of $163,282.88. Following the completion of the transaction, the chief executive officer now owns 1,374 shares of the company’s stock, valued at $181,807.68. The disclosure for this sale can be found here. Insiders sold a total of 25,198 shares of company stock worth $3,281,816 in the last ninety days. Corporate insiders own 7.80% of the company’s stock.

Several institutional investors and hedge funds have recently made changes to their positions in the business. HPM Partners LLC boosted its holdings in shares of United Therapeutics Corporation by 0.8% in the second quarter. HPM Partners LLC now owns 1,981 shares of the biotechnology company’s stock worth $257,000 after buying an additional 15 shares during the period. First Allied Advisory Services Inc. boosted its holdings in shares of United Therapeutics Corporation by 0.4% in the second quarter. First Allied Advisory Services Inc. now owns 4,579 shares of the biotechnology company’s stock worth $598,000 after buying an additional 19 shares during the period. Nomura Asset Management Co. Ltd. boosted its holdings in shares of United Therapeutics Corporation by 0.3% in the first quarter. Nomura Asset Management Co. Ltd. now owns 12,646 shares of the biotechnology company’s stock worth $1,712,000 after buying an additional 40 shares during the period. Fisher Asset Management LLC boosted its holdings in shares of United Therapeutics Corporation by 1.4% in the second quarter. Fisher Asset Management LLC now owns 3,169 shares of the biotechnology company’s stock worth $411,000 after buying an additional 45 shares during the period. Finally, Argent Capital Management LLC boosted its holdings in shares of United Therapeutics Corporation by 2.4% in the first quarter. Argent Capital Management LLC now owns 2,530 shares of the biotechnology company’s stock worth $343,000 after buying an additional 60 shares during the period.

United Therapeutics Corporation Company Profile

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).

Analyst Recommendations for United Therapeutics Corporation (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.